Transfusion Medicine Reviews
Volume 20, Issue 3 , Pages 190-206 , July 2006

An Overview of Prion Biology and the Role of Blood Filtration in Reducing the Risk of Transfusion-Transmitted Variant Creutzfeldt-Jakob Disease

References 

  1. Ghani AC, Donnelly CA, Ferguson NM, et al. Updated projections of future vCJD deaths in the UK. BMC Infect Dis. 2003;3:4
  2. Ghani AC, Ferguson NM, Donnelly CA, et al. Predicted vCJD mortality in Great Britain. Nature. 2000;406:583–584
  3. Ghani AC, Ferguson NM, Donnelly CA, et al. Estimation of the number of people incubating variant CJD. [letter] Lancet. 1998;352:1353–1354
  4. Glatzel M, Ott PM, Lindner T, et al. Human prion diseases: Epidemiology and integrated risk assessment. Lancet Neurol. 2003;2:757–763
  5. Ortolano GA, Sowemimo-Coker S, Schaffer J, et al. Prion biology in transfusion medicine: Implications for lab testing. MLO Med Lab Obs. 2005;10–22
  6. Will RG, Ironside JW, Zeidler M, et al. A new variant Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347:921–925
  7. Further precautionary measures on blood products announced. Department of Health press release on CJD/BSE (United Kingdom 98/076). Feb 26,1998
  8. Ricketts MN, Cashman NR, Stratton E, et al. Is Creutzfeldt-Jakob disease transmitted in blood?. Emerg Infect Dis. 1997;3:157–163
  9. Sullivan MT, Schonberger LB, Kessler D. Creutzfeldt-Jakob disease (CJD) investigational lookback study. Transfusion. 1997;37:2S;(suppl)
  10. Stratton E, Ricketts MN, Gully PR. Creutzfeldt-Jakob disease in Canada. Can Commun Dis Rep. 1996;22:57–61
  11. Foster PR. Prions and blood products. Ann Med. 2000;32:501–513
  12. Herzog C, Sales N, Etchegaray N, et al. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet. 2004;363:422–428
  13. Houston N, Foster J, Chong A, et al. Transmission of SE by blood transfusion in sheep. Lancet. 2000;356:999–1000
  14. Hunter N, Foster J, Chong A, et al. Transmission of prion disease by blood transfusion. J Gen Virol. 2002;83:2897–2905
  15. Hill AF, Zeidler M, Ironside J, et al. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet. 1997;349:99–100
  16. Western Mail. August 22, 2005
  17. Aguzzi A. Prions and the immune system: A journey through gut, spleen, and nerves. Adv Immunol. 2003;81:123–171
  18. Heppner FL, Musahl C, Arrighi I, et al. Prevention of scrapie pathogenesis by transgenic expression of anti–prion protein antibodies. Science. 2001;294:178–182
  19. Meier P, Genoud N, Prinz M, et al. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Cell. 2003;113:49–60
  20. Aguzzi A, Glatzel M, Montrasio F, et al. Interventional strategies against prion diseases. Nat Rev Neurosci. 2001;2:745–749
  21. Montrasio F, Frigg R, Glatzel M, et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science. 2000;288:1257–1259
  22. UK Department of Health http://www.dh.gov.uk
  23. Castilla J, Saa P, Soto C. Detection of prions in blood. Nat Med. 2005;11:982–985
  24. Llewelyn CA, Hewitt PE, Knight RSG, et al. Possible transmission of new variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363:417–421
  25. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:527–529
  26. Prusiner SB. Prions-Nobel lecture, December 8, 1997. Accessed on September 14, 2005 at http://nobelprize.org/medicine/laureates/1997/prusiner-lecture.pdf
  27. Aguzzi A, Weissmann C. Prion research: The next frontiers. Nature. 1997;389:795–798
  28. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136–144
  29. Basler K, Oesch B, Scott M, et al. Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. Cell. 1986;46:417–428
  30. Chesebro B, Race R, Wehrly K, et al. Identification of scrapie prion protein–specific mRNA in scrapie-infected and uninfected brain. Nature. 1985;315:331–333
  31. Oesch B, Westaway D, Walchli M, et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell. 1985;40:735–746
  32. Lindquist SL. Prion proteins: One surprise after another. Harvey Lect. 2002-2003;98:173–205
  33. Moudjou M, Treguer E, Rezaei H, et al. Glycan-controlled epitopes of prion protein include a major determinant of susceptibility to sheep scrapie. J Virol. 2004;78:9270–9276
  34. Bendheim PE, Brown HR, Rudelli RD, et al. Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology. 1992;42:149–156
  35. Harris DA. Cellular biology of prion diseases. Clin Microbiol Rev. 1999;12:429–444
  36. Prusiner SB. Creutzfeldt-Jakob disease and scrapie prions. Alzheimer Dis Assoc Disord. 1989;3:52–78
  37. Stahl N, Borchelt DR, Hsiao K, et al. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell. 1987;51:229–240
  38. Pan T, Li R, Wong BS, et al. Novel antibody-lectin enzyme-linked immunosorbent assay that distinguishes prion proteins in sporadic and variant cases of Creutzfeldt-Jakob disease. J Clin Microbiol. 2005;43:1118–1126
  39. Thuring CM, Erkens JH, Jacobs JG, et al. Discrimination between scrapie and bovine spongiform encephalopathy in sheep by molecular size, immunoreactivity, and glycoprofile of prion protein. J Clin Microbiol. 2004;42:972–980
  40. Bosques CJ, Imperiali B. The interplay of glycosylation and disulfide formation influences fibrillization in a prion protein fragment. Proc Natl Acad Sci U S A. 2003;100:7593–7598
  41. Kuczius T, Groschup MH. Differences in proteinase K resistance and neuronal deposition of abnormal prion proteins characterize bovine spongiform encephalopathy (BSE) and scrapie strains. Mol Med. 1999;5:406–418
  42. Race R, Jenny A, Sutton D. Scrapie infectivity and proteinase K–resistant prion protein in sheep placenta, brain, spleen, and lymph node: Implications for transmission and antemortem diagnosis. J Infect Dis. 1998;178:949–953
  43. Büeler HR, Fischer M, Lang Y, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature. 1992;356:577–582
  44. Collinge J, Whittington MA, Sidle KC, et al. Prion protein is necessary for normal synaptic function. Nature. 1994;370:295–297
  45. Tobler I, Gaus SE, Deboer T, et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature. 1996;380:639–642
  46. Büeler HR, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993;73:1339–1347
  47. Mouillet-Richard S, Ermonval M, Chebassier C, et al. Signal transduction through prion protein. Science. 2000;289:1925–1928
  48. Brown DR, Schulz-Schaeffer WJ, Schmidt B, et al. Prion protein–deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp Neurol. 1997;146:104–112
  49. Brown DR, Wong BS, Hafiz F, et al. Normal prion protein has an activity like that of superoxide dismutase. J Biochem. 1999;344:1–5(Pt. 1)
  50. Sakudo A, Lee DC, Saeki K, et al. Impairment of superoxide dismutase activation by N-terminally truncated prion protein (PrP) in PrP-deficient neuronal cell line. Biochem Biophys Res Commun. 2003;308:660–667
  51. Hutter G, Heppner FL, Aguzzi A. Superoxide dismutase activity of cellular prion protein in vivo. Biol Chem. 2003;384:1279–1285
  52. Waggoner DJ, Drisaldi B, Bartnikas TB, et al. Brain copper content and cuproenzyme activity do not vary with prion protein expression level. J Biol Chem. 2000;275:7455–7458
  53. Kurschner C, Morgan JI, Yehiely F, et al. The cellular prion protein (PrP) selectively binds to Bcl-2 in the yeast two-hybrid system: Identification of candidate proteins binding to prion protein. Brain Res Mol Brain Res. 1995;30:165–168
  54. Gorodinsky A, Harris DA. Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin. J Cell Biol. 1995;129:619–627
  55. Harmey JH, Doyle D, Brown V, et al. The cellular isoform of the prion protein, PrPc, is associated with caveolae in mouse neuroblastoma (N2a) cells. Biochem Biophys Res Commun. 1995;210:753–759
  56. Rieger R, Edenhofer F, Lasmezas CI, et al. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med. 1997;3:1383–1388
  57. Fischer MB, Roeckl C, Parizek P, et al. Binding of disease-associated prion protein to plasminogen. Nature. 2000;408:479–483
  58. Schmitt-Ulms G, Legname G, Baldwin MA, et al. Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. J Mol Biol. 2001;314:1209–1225
  59. Watarai M, Kim S, Erdenebaatar J, et al. Cellular prion protein promotes Brucella infection into macrophages. J Exp Med. 2003;198:5–17
  60. Aguzzi A, Hardt WD. Dangerous liaisons between a microbe and the prion protein. J Exp Med. 2003;198:1–4
  61. Concepcion GP, David MP, Padlan EA. Why don't humans get scrapie from eating sheep? A possible explanation based on secondary structure predictions. Med Hypotheses. 2005;64:919–924
  62. Kong Q, Huang S, Zou W, et al. Chronic wasting disease of elk: Transmissibility to humans examined by transgenic mouse models. J Neurosci. 2005;25:7944–7949
  63. Hamir AN, Kunkle RA, Cutlip RC, et al. Experimental transmission of chronic wasting disease agent from mule deer to cattle by the intracerebral route. J Vet Diagn Invest. 2005;17:276–281
  64. Ironside JW, Head MW. Neuropathology and molecular biology of variant Creutzfeldt-Jakob disease. Curr Top Microbiol Immunol. 2004;284:133–159
  65. Concepcion GP, Padlan EA. The codon for the methionine at position 129 (M129) in the human prion protein provides an alternative initiation site for translation and renders individuals homozygous for M129 more susceptible to prion disease. Med Hypotheses. 2005;65:865–867
  66. Lawson VA, Collins SJ, Masters CL, et al. Prion protein glycosylation. J Neurochem. 2005;93:793–801
  67. Atkinson PH. Glycosylation of prion strains in transmissible spongiform encephalopathies. Aust J Vet. 2004;82:292–299
  68. Bastian FO, McDermott ME, Perry AS, et al. Safe method for isolation of prion protein and diagnosis of Creutzfeldt-Jakob disease. J Virol Methods. 2005;130:133–139
  69. Matucci A, Zanusso G, Gelati M, et al. Analysis of mammalian scrapie protein by novel monoclonal antibodies recognizing distinct prion protein glycoforms: An immunoblot and immunohistochemical study at the light and electron microscopic levels. Brain Res Bull. 2005;65:155–162
  70. Khalili-Shirazi A, Summers L, Linehan J, et al. PrP glycoforms are associated in a strain-specific ratio in native PrPSc. J Gen Virol. 2005;86:2635–2644
  71. Chesebro B, Trifilo M, Race R, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science. 2005;308:1435–1439
  72. Sander P, Hamann H, Drogemuller C, et al. Bovine prion protein gene (PRNP) promoter polymorphisms modulate PRNP expression and may be responsible for differences in BSE susceptibility. J Biol Chem. 2005;280:37408–37414
  73. Weissmann C. Birth of a prion: Spontaneous generation revisited. Cell. 2005;122:165–168
  74. Norstrom EM, Mastrianni JA. The AGAAAAGA palindrome in PrP is required to generate a productive PrPSc-PrPC complex that leads to prion propagation. J Biol Chem. 2005;280:27236–27243
  75. Silveira JR, Raymond GJ, Hughson AG, et al. The most infectious prion protein particles. Nature. 2005;437:257–261
  76. Creutzfeldt H. Uber eine eigenartige herdformige erkrankkung des zentralnervensystems. Z Ges Neurol Psychiatry. 1920;57:1–18
  77. Jakob A. Uber eigenartige erkrankungen des zentralnervensystems mit bemerkenswerten anatomischen befunde (spastische pseudosklerose-encephomyelopathie mit disseminierten degenerationsherden). Z Ges Neurol Psychiatry. 1921;64:147–228
  78. Alper T, Cramp WA, Haig DA, et al. Does the agent of scrapie replicate without nucleic acid?. Nature. 1967;214:764–766
  79. Griffith JS. Self-replication and scrapie. Nature. 1967;215:1043–1044
  80. Gajdusek DC, Gibbs CJ, Alpers M. Experimental transmission of a kuru-like syndrome to chimpanzees. Nature. 1966;209:794–796
  81. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob Disease in the UK. Lancet. 1996;347:921–925
  82. Belay ED, Maddox RA, Williams ES, et al. Chronic wasting disease and potential transmission to humans. Emerg Infect Dis. 2004;10:977–984
  83. Ironside JW, Head MW. Neuropathology and molecular biology of variant Creutzfeldt-Jakob Disease. Curr Top Microbiol Immunol. 2004;284:133–159
  84. Gambetti P, Kong Q, Zou W, et al. Sporadic and familial CJD: Classification and characterization. Br Med Bull. 2003;66:213–239
  85. Harrison PJ, Roberts GW. “Life, Jim, but not as we know it”? Transmissible dementias and the prion protein. Br J Psychiatry. 1991;158:457–470
  86. Boller F, Lopez OL, Moossy J. Diagnosis of dementia: Clinicopathologic correlations. Neurology. 1989;39:76–79
  87. Brown P. Central nervous system amyloidoses: A comparison of Alzheimer's disease and Creutzfeldt-Jakob disease. Neurology. 1989;39:1103–1105
  88. Prusiner SB. Some speculations about prions, amyloid, and Alzheimer's disease. N Engl J Med. 1984;310:661–663
  89. Mortality from Alzheimer Disease—United States, 1979-1987 MMWR November 02, 1990; 39:785-786,788 http://www.cdc.gov/mmwr/preview/mmwrhtml/00001820.htm
  90. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  91. Prion disease-spongiform encephalopathies unveiled. Lancet. 1990;336:21–22
  92. Manuelidis EE, Manuelidis L. Suggested links between different types of dementias: Creutzfeldt-Jakob disease, Alzheimer disease, and retroviral CNS infections. Alzheimer Dis Assoc Disord. 1989;3:100–109
  93. Boulton F. The impact of variant CJD on transfusion practices in the UK. Transfus Apheresis Sci. 2003;28:107–116
  94. The vCJD Working party of the Standing Advisory Committee on Transfusion Transmitted Infections. Creutzfeld-Jakob disease. Joint UKBTS/NIBSC Position statements, April, 2004: http://www.transfusionguidelines.org.uk/docs/pdfs/position_statement_01_2004_04.pdf
  95. Flanagan P, Barbara JA. Prion disease and blood. Transfus Med. 1996;6:213–215
  96. Canadian Blood Services press release, August 15, 2005
  97. United Kingdom Spongiform Encephalopathy Advisory Committee (SEAC) Annual Report 1997-1998: p10. Department of Environment, Food and Rural Affairs:3/04 Page Street, London SW1P 4PO, England, UK
  98. Murphy MF. New variant Creutzfeldt-Jakob disease (nvCJD): The risk of transmission by blood transfusion and the potential benefit of leukocyte-reduction of blood components. Transfus Med Rev. 1999;13:75–83
  99. Gregori L, McCombie N, Palmer D, et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet. 2004;364:529–531
  100. Sowemimo-Coker SO, Kim A, Zinn F, et al. Removal of prion (PrP) from red cell concentrates (RCC) with prototype of a prion removal filter (PrRF). Transfusion. 2003;43:7A–8A(Abstr, Suppl)
  101. FDA final guidance—Revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by blood and blood products. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). January 2002
  102. Brown P, Rohwer RG, Dunstan BC, et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion. 1998;38:810–816
  103. Brown P, Cervenakova L, Diringer H. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. J Lab Clin Med. 2001;137:5–13
  104. Sowemimo-Coker SO, Kascsak R, Kim A, et al. Removal of exogenous (spiked) and endogenous prion infectivity from red cell concentrates using a new prototype of leukocyte reduction filter. Transfusion. 2005;45:1839–1844
  105. Ortolano GA, Wilkins K, Cervia JS. Characterization of prion removal devices for blood products. Transfus Med Hematother. 2005;32:245–251
  106. Sowemimo-Coker SO, Pesci S, Andrade F, Removal of infectious prions from red cell concentrates with leukotrap affinity prion reduction filter. Vox Sang. [Epub ahead of print: http://www.blackwell-synergy.com/toc/vox/0/0]
  107. Lee DC, Stenland CJ, Miller JLC, et al. A direct relationship between the portioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion. 2001;41:449–455
  108. Liao YC, Lebo RV, Clawson GA, et al. Human prion protein cDNA: Molecular cloning, chromosomal mapping, and biological implications. Science. 1986;233:364–367
  109. Bendheim PE, Bockman JM, McKinley MP, et al. Scrapie and Creutzfeldt-Jakob disease prion proteins share physical properties and antigenic determinants. Proc Natl Acad Sci U S A. 1985;82:997–1001
  110. Reed , Muench . A simple method for estimating fifty percent endpoint. Am J Hyg. 1938;27:493–497
  111. Council of Europe . Guide to the preparation, use and quality assurance of blood components. 11th ed.. Strasbourg: Council of Europe Publishing; 2004;
  112. Food and Drug Administration Department of Health and Human Services Recommendations and licensure requirements for leukocyte reduced blood products. Memorandum to all registered blood establishments, May 29, 1996.
  113. UK National Blood Service . Guidelines for the Blood Transfusion Services in the United Kingdom. 6th ed. Norwich: The Stationary Office; 2002;
  114. Heaton WAL, Holme S, Smith K, et al. Effects of 3-5 log10 pre-storage leukocyte depletion on red cell storage and metabolism. Br J Haematol. 1994;87:363–368
  115. Pietersz RNI, de Korte D, Reesink HW, et al. Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation. Vox Sang. 1989;56:145–150
  116. Hogman CF. Liquid-stored red blood cells for transfusion. Vox Sang. 1999;76:67–77
  117. Hess JR, Kagen LR, van der Meer PF, et al. Interlaboratory comparison of red cell ATP, 2,3-diphosphoglycerate and hemolysis measurements. Vox Sang. 2005;89:44–48
  118. In:  Brecher ME,  Leger RL,  Linden JV editor. Collection, preparation, storage and distribution of components from whole blood donation. Chapter 8. AABB Technical Manual. 15th ed. Bethesda: AAAB; 2005;p. 175–202
  119. Hogman CF, Merryman HT. Storage parameters affecting red cell survival and functions after transfusion. Transfus Med Rev. 1999;13:275–276
  120. Heaton A, Keegan T, Holme S. In vivo regeneration of red cell 2,3-diphosphoglycerate following transfusion of DPG-depleted AS-1, AS-3 and CPDA-1 red cells. Br J Haematol. 1989;71:181–186
  121. Hogman CF. Preparation and preservation of red cells. Vox Sang. 1998;74:177–187(suppl 2)
  122. Greenwalt TJ, Zehner Sostok C, Dumaswala UJ. Studies in red blood cell preservation. 1. Effect of other formed elements. Vox Sang. 1990;58:85–89
  123. McLellan SA, Walsh TS, McClellan DBL. Should we demand fresh red blood cells for perioperative and critically ill patients?. Br J Anaesth. 2002;89:537–540
  124. Dumaswala UJ, Dumaswala RU, Levin DS, et al. Improved red blood cell preservation correlates with decreased loss of bands 3, 4.1, acetylcholinesterase and lipids in microvesicles. Blood. 1996;87:1612–1616
  125. Krailadsiri P, Perry R, Drummond O, et al. The effects of leukocyte depletion on the generation and removal of microvesicles and prion related protein in blood components. Transfus Apheresis Sci. 2001;25:177–178
  126. Saunders C, Herbert P, Rowe G, et al. In-vitro evaluation of PALL leukotrap affinity prion reduction filter as a secondary device following primary leucoreduction. Vox Sang. 2005;89:220–228
  127. Bruce LJ, Beckmann R, Ribeiro ML, et al. A band 3-based macrocomplex of integral and peripheral proteins in the RBC membrane. Blood. 2003;101:4180–4188
  128. Stewart A, Urbaniak S, Turner M, et al. The application of a new quantitative assay for the monitoring of integrin-associated protein CD47 on red blood cells during storage and comparison with the expression of CD47 and phospatidylserine with flow cytometry. Transfusion. 2005;45:1496–1503
  129. Nelson E, Taylor H, Whitley P, et al. Evaluation of in vivo red blood cell recovery after processing with a new filter designed to remove prions. Vox Sang. 2005;89:20;(abstr, suppl 2)
  130. Wilson K, Wilson M, Herbert PC, et al. The application of the precautionary principle to the blood system: The Canadian blood system's vCJD donor deferral policy. Transfus Med Rev. 2003;17:89–94

PII: S0887-7963(06)00012-5

doi: 10.1016/j.tmrv.2006.03.007

Transfusion Medicine Reviews
Volume 20, Issue 3 , Pages 190-206 , July 2006

Article Tools

* Image Usage & Resolution